Limbic pallidal adaptations following long-term cessation of dopaminergic transmission: Lack of upregulation of dopamine receptor function

Experimental Neurology

Volumn 186, Issue 2, 2004, Pages 145-157

  Heidenreich, Byron A ^a,b   Mitrovic, Igor ^a,c   Battaglia, George ^a   Napier, T Celeste ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b ILLINOIS STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

3,4 dihydroxyphenylacetic acid; 5 HIAA; 5 HT; 5 hydroxyindoleacetic acid; 5 hydroxytryptamine; 6 Hydroxydopamine; D 1 antagonists; D1 agonists; DA; DOPAC; Dopamine; Electrophysiology; GP; SCH23390; SKF38393; Ventral pallidum

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE RECEPTOR BLOCKING; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ELECTROPHYSIOLOGY; FOREBRAIN; GLOBUS PALLIDUS; IONTOPHORESIS; LIMBIC CORTEX; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR SENSITIVITY; RECEPTOR UPREGULATION; SPIKE WAVE;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; 2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ACTION POTENTIALS; ANIMALS; BINDING SITES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; FUNCTIONAL LATERALITY; GLOBUS PALLIDUS; IMMUNOHISTOCHEMISTRY; IONTOPHORESIS; MALE; NEURONS; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; SULPIRIDE; SYMPATHOLYTICS; SYNAPTIC TRANSMISSION; TIME; TYROSINE 3-MONOOXYGENASE;

EID: 1542617765     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2003.11.004     Document Type: Article

References (64)

1. Bengtson C.P., Osborne P.B. Electrophysiological properties of anatomically identified ventral pallidal neurons in rat brain slices. Ann. N. Y. Acad. Sci. 877:1999;691-694.
2. Bergman H., Wichmann T., Karmon B., DeLong M.R. The primate subthalamic nucleus: II. Neuronal activity in the MPTP model of parkinsonism. J. Neurophys. 72:1994;507-520.
3. Bezard E., Boraud T., Bioulac B., Gross C.E. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. Eur. J. Neurosci. 11:1999;2167-2170.
4. Bioulac B., Boulard G., Vincent J.D., Puil E. Effects of dopamine agonists on neurones in the caudate nucleus and cerebral cortex of cats chronically treated with neuroleptics. Neuropharmacology. 17:1978;965-969.
5. Breese G.R., Duncan G.E., Napier T.C., Bondy S.C., Iorio L.C., Mueller R.A. 6-Hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J. Pharmacol. Exp. Ther. 240:1987;167-176.
6. Calabresi P., Mercuri N.B., Sancesario G., Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain. 116:1993;433-452.
7. Carlson J.H., Bergstrom D.A., Demo S.D., Walters J.R. Acute reduction of dopamine levels alters responses of basal ganglia neurons to selective D-1 and D-2 dopamine receptor stimulation. Eur. J. Pharmacol. 152:1988;289-300.
8. Carlson J.H., Bergstrom D.A., Demo S.D., Walters J.R. Nigrostriatal lesion alters neurophysiological responses to selective and nonselective D-1 and D-2 dopamine agonists in rat globus pallidus. Synapse. 5:1990;83-93.
9. Churchill L., Klitenick M.A., Kalivas P.W. Dopamine depletion reorganizes projections from the nucleus accumbens and ventral pallidum that mediate opioid-induced motor activity. J. Neurosci. 18:1998;8074-8085.
10. Creese I., Chen A. Selective D-1 dopamine receptor increase following chronic treatment with SCH 23390. Eur. J. Pharmacol. 109:1985;127-128.
11. Debonnel G., De Montigny C. Increased neuronal responsiveness to cholecystokinin and dopamine induced by lesioning mesolimbic dopaminergic neurons: an electrophysiological study in the rat. Synapse. 2:1988;537-545.
12. Feltz P., De Champlain J. Enhanced sensitivity of caudate neurones to microiontophoretic injections of dopamine in 6-hydroxydopamine treated cats. Brain Res. 43:1972;601-605.
13. Feltz P., De Champlain J. Persistence of caudate unitary responses to nigral stimulation after destruction and functional impairment of the striatal dopaminergic terminals. Brain Res. 43:1972;595-600.
14. Filion M., Tremblay L. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res. 547:1991;142-151.
15. Galarraga E., Bargas J., Martinez-Fong D., Aceves J. Spontaneous synaptic potentials in dopamine-denervated neostriatal neurons. Neurosci. Lett. 81:1987;351-355.
16. Gandolfi O., Dall'Olio R., Vaccheri A., Roncada P., Montanaro N. Responses to selective D-1 and D-2 agonists after repeated treatment with selective D-1 and D-2 antagonists. Pharmacol., Biochem. Behav. 30:1988;463-469.
17. Gandolfi O., Roncada P., Dall'Olio R. Single or repeated administrations of SCH 23390 fail to affect serotonergic neurotransmission. Neurosci. Lett. 92:1988;192-196.
18. Geula C., Slevin J.T. Substantia nigra 6-hydroxydopamine lesions alter dopaminergic synaptic markers in the nucleus basalis magnocellularis and striatum of rats. Synapse. 4:1989;248-253.
19. Gong W., Neill D.B., Lynn M., Justice J.B. Jr. Dopamine D1/D2 agonists injected into nucleus accumbens and ventral pallidum differentially affect locomotor activity depending on site. Neuroscience. 93:1999;1349-1358.
20. Groenewegen H.J., Berendse H.W. Connections of the subthalamic nucleus with ventral striatopallidal parts of the basal ganglia in the rat. J. Comp. Neurol. 294:1990;607-622.
21. Heidenreich B.A., Napier T.C. Effects of serotonergic 5-HT1A and 5-HT1B ligands on ventral pallidal neuronal activity. NeuroReport. 11:2000;2849-2853.
22. Heidenreich B.A., Mailman R.B., Nichols D.E., Napier T.C. Partial and full dopamine D1 agonists produce comparable increases in ventral pallidal neuronal activity: contribution of endogenous dopamine. J. Pharmacol. Exp. Ther. 273:1995;516-525.
23. Heimer L., Wilson R.D. The subcortical projections of the allocortex: similarities in the neural associations of the hippocampus, the piriform cortex, and the neocortex. Santini M. Golgi Centennial Symp. Proc. 1975;177-193 Raven Press, New York.
24. 3H] SCH23390-labeled D1 dopamine receptors in rat striatum. Eur. J. Pharmacol. 121:1986;31-38.
25. Hu X.-T., Wang R.Y. Haloperidol and clozapine: differential effects on the sensitivity of caudate-putamen neurons to dopamine agonists and cholecystokinin following one month continuous treatment. Brain Res. 486:1989;325-333.
26. Hu X.-T., Wachtel S.R., Galloway M.P., White F.J. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation. J. Neurosci. 10:1990;2318-2329.
27. Johnson P.I., Napier T.C. GABA and glutamate-evoked responses in the rat ventral pallidum are modulated by dopamine. Eur. J. Neurosci. 9:1997;1397-1406.
28. Jones B.E., Cuello A.C. Afferents to the basal forebrain cholinergic cell area from pontomesencephalic-catecholamine, serotonin, and acetylcholine-neurons. Neuroscience. 31:1989;37-61.
29. Khateb A., Fort P., Alonso A., Jones B.E., Muhlethaler M. Pharmacological and immunohistochemical evidence for serotonergic modulation of cholinergic nucleus basalis neurons. Eur. J. Neurosci. 5:1993;541-547.
30. Kish L.J., Palmer M.R., Gerhardt G.A. Multiple single-unit recordings in the striatum of freely moving animals: effects of apomorphine and D-amphetamine in normal and unilateral 6-hydroxydopamine-lesioned rats. Brain Res. 833:1999;58-70.
31. Kreiss D.S., Mastropietro C.W., Rawji S.S., Walters J.R. The response of subthalamic nucleus neurons to dopamine receptor stimulation in a rodent model of Parkinson's disease. J. Neurosci. 17:1997;6807-6819.
32. Lappalainen J., Hietala J., Koulu M., Seppälä T., Sjöholm B., Syvälahti E. Chronic treatment with SCH 23390 and haloperidol: effects on dopaminergic and serotonergic mechanisms in rat brain. J. Pharmacol. Exp. Ther. 252:1990;845-852.
33. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
34. Maslowski R.J., Napier T.C. Dopamine D1 and D2 receptor agonists induce opposite changes in the firing rate of ventral pallidal neurons. Eur. J. Pharmacol. 200:1991;103-112.
35. Maslowski-Cobuzzi R.J., Napier T.C. Activation of dopaminergic neurons modulates ventral pallidal responses evoked by amygdala stimulation. Neuroscience. 62:1994;1103-1120.
36. McQuade R.D., Ford D., Duffy R.A., Chipkin R.E., Iorio L.C., Barnett A. Serotonergic component of SCH 23390: in vitro and in vivo binding analyses. Life Sci. 43:1988;1861-1869.
37. Miller W.C., DeLong M.R. Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. Carpenter M.B., Jayaraman A. The Basal Ganglia:II Structure and Function-Current Concepts. 1987;415-427 Plenum, New York.
38. Mitrovic I., Napier T.C. Mu and kappa opioid agonists modulate ventral tegmental area input to the ventral pallidum. Eur. J. Neurosci. 15:2002;257-268.
39. Muma N.A., Lee J.M., Gorman L., Heidenreich B.A., Mitrovic I., Napier T.C. 6-Hydroxydopamine-induced lesions of dopaminergic neurons alter the function of postsynaptic cholinergic neurons without changing cytoskeletal proteins. Exp. Neurol. 168:2001;135-143.
40. Napier T.C. Contribution of the amygdala and nucleus accumbens to ventral pallidal responses to dopamine agonists. Synapse. 10:1992;110-119.
41. Napier T.C., Maslowski-Cobuzzi R.J. Electrophysiological verification for the presence of D1 and D2 dopamine receptors within the ventral pallidum. Synapse. 17:1994;160-166.
42. Napier T.C., Potter P.E. Dopamine in the rat ventral pallidum/substantia innominata: biochemical and electrophysiological studies. Neuropharmacology. 28:1989;757-760.
43. Napier T.C., Simson P.E., Givens B.S. Dopamine electrophysiology of ventral pallidal/substantia innominata neurons: comparison with the dorsal globus pallidus. J. Pharmacol. Exp. Ther. 258:1991;249-262.
44. Nauta W.J.H., Smith G.P., Faull R.L.M., Domesick V.B. Efferent connections and nigral afferents of the nucleus accumbens septi in the rat. Neuroscience. 3:1978;385-401.
45. Nisenbaum E.S., Stricker E.M., Zigmond M.J., Berger T.W. Long-term effects of dopamine-depleting brain lesions on spontaneous activity of type II striatal neurons: relation to behavioral recovery. Brain Res. 398:1986;221-230.
46. Norcross K., Spehlmann R. Decreased sensitivity of caudate neurons to microiontophoretic dopamine in dopamine-depleted caudate nucleus. Brain Res. 156:1978;175-180.
47. Pitts D.K., Kelland M.D., Shen R.-Y., Freeman A.S., Chiodo L.A. Statistical analysis of dose-response curves in extracellular electrophysiological studies of single neurons. Synapse. 5:1990;281-293.
48. Rothblat D.S., Schneider J.S. Response of caudate neurons to stimulation of intrinsic and peripheral afferents in normal, symptomatic, and recovered MPTP-treated cats. J. Neurosci. 13:1993;4372-4378.
49. Russchen F.T., Amaral D.G., Price J.L. The afferent connections of the substantia innominata in the monkey, Macaca fascicularis. J. Comp. Neurol. 242:1985;1-27.
50. Schultz W. Depletion of dopamine in the striatum as an experimental model of Parkinsonism: direct effects and adaptive mechanisms. Prog. Neurobiol. 18:1982;121-166.
51. Schultz W., Ungerstedt U. Short-term increase and long-term reversion of striatal cell activity after degeneration of the nigrostriatal dopamine system. Exp. Brain Res. 33:1978;159-171.
52. Schultz W., Ungerstedt U. Striatal cell supersensitivity to apomorphine in dopamine-lesioned rats correlated to behaviour. Neuropharmacology. 17:1978;349-353.
53. Semba K., Reiner P.B., McGeer E.G., Fibiger H.C. Brainstem afferents to the magnocellular basal forebrain studied by axonal transport, immunohistochemistry, and electrophysiology in the rat. J. Comp. Neurol. 267:1988;433-453.
54. Siggins G.R., Hoffer B.J., Ungerstedt U. Electrophysiological evidence for involvement of cyclic adenosine monophosphate in dopamine responses of caudate neurons. Life Sci. 15:1974;779-792.
55. Simson P.E., Johnson K.B., Jurevics H.A., Criswell H.E., Napier T.C., Duncan T.C., Mueller R.A., Breese G.R. Augmented sensitivity of D1-dopamine receptors in lateral but not medial striatum after 6-hydroxydopamine-induced lesions in the neonatal rat. J. Pharmacol. Exp. Ther. 263:1992;1454-1463.
56. Skirboll L.R., Bunney B.S. The effects of acute and chronic haloperidol treatment on spontaneously firing neurons in the caudate nucleus of the rat. Life Sci. 25:1979;1419-1433.
57. Spooren W.P.J.M., Piosik P.A., Cools A.R. Dopamine D1 receptors in the sub-commissural part of the globus pallidus and their role in oro-facial dyskinesias in cats. Eur. J. Pharmacol. 204:1991;217-222.
58. Turner M.S., Lavin A., Grace A.A., Napier T.C. Regulation of limbic information outflow by the subthalamic nucleus: excitatory amino acid projections to the ventral pallidum. J. Neurosci. 21:2001;2820-2832.
59. Turner M.S., Mignon L., Napier T.C. Alterations in responses of ventral pallidal neurons to excitatory amino acids after long-term dopamine depletion. J. Pharmacol. Exp. Ther. 301:2002;371-381.
60. Yang C.R., Mogenson G.J. Ventral pallidal neuronal responses to dopamine receptor stimulation in the nucleus accumbens. Brain Res. 489:1989;237-246.
61. Yarbrough G.G. Supersensitivity of caudate neurones after repeated administration of haloperidol. Eur. J. Pharmacol. 31:1975;367-369.
62. Zaborszky L. Afferent connections of the forebrain cholinergic projection neurons, with special reference to monoaminergic and peptidergic fibers. Frotscher M., Misgeld U. Central Cholinergic Synaptic Transmission. 1989;12-32 Birkhauser, Basal.
63. Zarzecki P., Blake D.J., Somjen G.G. Neurological disturbances, nigrostriate synapses, and iontophoretic dopamine and apomorphine after haloperidol. Exp. Neurol. 57:1977;956-970.
64. Zigmond M.J., Abercrombie E.D., Berger T.W., Grace A.A., Stricker E.M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13:1990;290-296.